Understanding Tumor Treating Fields as a Novel Modality in Pancreatic Cancer

Philip A. Philip, MD, discusses how tumor treating fields work and their role in locally advanced pancreatic cancer following the Optune Pax FDA approval.

Philip A. Philip, MD, discusses TTFields in pancreatic cancer and what phase 3 data has shown in locally advanced disease.

Philip A. Philip, MD, discusses TTFields, the recent approval of this modality in pancreatic cancer, and phase 3 data in locally advanced disease.

Andrew H. Ko, MD, discusses how TTFields works and data that supported the FDA approval of Optune Pax for patients with pancreatic cancer.

Andrew Ko, MD, details the safety profile of Optune Pax in the PANOVA-3 trial for patients with locally advanced pancreatic cancer.

Vincent Picozzi, MD, discusses the PANOVA-3 data supporting the approval of Optune Pax and the future of TTFields in pancreatic cancer.

Vincent Picozzi, MD, discusses the FDA approval of Optune Pax for locally advanced pancreatic cancer and the criteria for optimal patient selection.